Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Saved in:
| Title: | Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. |
|---|---|
| Authors: | Fischer T; Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA., Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2010 Oct 01; Vol. 28 (28), pp. 4339-45. Date of Electronic Publication: 2010 Aug 23. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 20733134 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Fischer+T%22">Fischer T</searchLink>; Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.<br /><searchLink fieldCode="AU" term="%22Stone+RM%22">Stone RM</searchLink><br /><searchLink fieldCode="AU" term="%22Deangelo+DJ%22">Deangelo DJ</searchLink><br /><searchLink fieldCode="AU" term="%22Galinsky+I%22">Galinsky I</searchLink><br /><searchLink fieldCode="AU" term="%22Estey+E%22">Estey E</searchLink><br /><searchLink fieldCode="AU" term="%22Lanza+C%22">Lanza C</searchLink><br /><searchLink fieldCode="AU" term="%22Fox+E%22">Fox E</searchLink><br /><searchLink fieldCode="AU" term="%22Ehninger+G%22">Ehninger G</searchLink><br /><searchLink fieldCode="AU" term="%22Feldman+EJ%22">Feldman EJ</searchLink><br /><searchLink fieldCode="AU" term="%22Schiller+GJ%22">Schiller GJ</searchLink><br /><searchLink fieldCode="AU" term="%22Klimek+VM%22">Klimek VM</searchLink><br /><searchLink fieldCode="AU" term="%22Nimer+SD%22">Nimer SD</searchLink><br /><searchLink fieldCode="AU" term="%22Gilliland+DG%22">Gilliland DG</searchLink><br /><searchLink fieldCode="AU" term="%22Dutreix+C%22">Dutreix C</searchLink><br /><searchLink fieldCode="AU" term="%22Huntsman-Labed+A%22">Huntsman-Labed A</searchLink><br /><searchLink fieldCode="AU" term="%22Virkus+J%22">Virkus J</searchLink><br /><searchLink fieldCode="AU" term="%22Giles+FJ%22">Giles FJ</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2010 Oct 01; Vol. 28 (28), pp. 4339-45. <i>Date of Electronic Publication: </i>2010 Aug 23. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=20733134 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1200/JCO.2010.28.9678 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 4339 Titles: – TitleFull: Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fischer T – PersonEntity: Name: NameFull: Stone RM – PersonEntity: Name: NameFull: Deangelo DJ – PersonEntity: Name: NameFull: Galinsky I – PersonEntity: Name: NameFull: Estey E – PersonEntity: Name: NameFull: Lanza C – PersonEntity: Name: NameFull: Fox E – PersonEntity: Name: NameFull: Ehninger G – PersonEntity: Name: NameFull: Feldman EJ – PersonEntity: Name: NameFull: Schiller GJ – PersonEntity: Name: NameFull: Klimek VM – PersonEntity: Name: NameFull: Nimer SD – PersonEntity: Name: NameFull: Gilliland DG – PersonEntity: Name: NameFull: Dutreix C – PersonEntity: Name: NameFull: Huntsman-Labed A – PersonEntity: Name: NameFull: Virkus J – PersonEntity: Name: NameFull: Giles FJ IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2010 Oct 01 Type: published Y: 2010 Identifiers: – Type: issn-electronic Value: 1527-7755 Numbering: – Type: volume Value: 28 – Type: issue Value: 28 Titles: – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Type: main |
| ResultId | 1 |
